PT  - JOURNAL ARTICLE
AU  - Samira Luisa Apostolos-Pereira
AU  - Lis Campos Ferreira
AU  - Mateus Boaventura
AU  - Nise Alessandra de Carvalho Sousa
AU  - Gabriela Joca Martins
AU  - José Arthur d'Almeida
AU  - Milena Pitombeira
AU  - Lucas Silvestre Mendes
AU  - Thiago Fukuda
AU  - Hideraldo Luíz Souza Cabeça
AU  - Luciano Chaves Rocha
AU  - Bianca Santos de Oliveira
AU  - Carla Renata Vieira Stella
AU  - Enedina Maria Lobato de Oliveira
AU  - Leizian de Souza Amorim
AU  - Andréa Ferrari de Castro
AU  - Antonio Pereira Gomes Neto
AU  - Guilherme Diogo Silva
AU  - Lucas Bueno
AU  - Maria de Morais Machado
AU  - Rafael Castello Dias-Carneiro
AU  - Ronaldo Maciel Dias
AU  - Alvaro Porto Moreira
AU  - Ana Piccolo
AU  - Anderson Kuntz Grzesiuk
AU  - Andre Muniz
AU  - Caio Diniz Disserol
AU  - Claudia Ferreira Vasconcelos
AU  - Damacio Kaimen-Maciel
AU  - Denise Sisterolli Diniz
AU  - Elizabeth Comini-Frota
AU  - Fernando Coronetti Rocha
AU  - Gutemberg Augusto Cruz dos Santos
AU  - Yara Dadalti Fragoso
AU  - Guilherme Sciascia do Olival
AU  - Heloisa Helena Ruocco
AU  - Heloise Helena Siqueira
AU  - Henry Koity Sato
AU  - José Alexandre Figueiredo, Jr
AU  - Leandro Cortoni Calia
AU  - Mario Emilio Teixeira Dourado, Jr
AU  - Letícia Scolari
AU  - Herval Ribeiro Soares Neto
AU  - Luiz Melges
AU  - Marcus Vinicius Magno Gonçalves
AU  - Maria Lucia Vellutini Pimentel
AU  - Marlise de Castro Ribeiro
AU  - Omar Gurrola Arambula
AU  - Paulo Diniz da Gama
AU  - Renata Leite Menon
AU  - Rodrigo Barbosa Thomaz
AU  - Rogério de Rizo Morales
AU  - Silvana Sobreira
AU  - Suzana Nunes Machado
AU  - Taysa Gonsalves Jubé Ribeiro
AU  - Valéria Coelho Santa Rita Pereira
AU  - Vanessa Maia Costa
AU  - Adaucto Wanderley da Nóbrega Junior
AU  - Soniza Vieira Alves-Leon
AU  - Marilia Mamprim de Morais Perin
AU  - Eduardo Donadi
AU  - Tarso Adoni
AU  - Sidney Gomes
AU  - Maria Brito Ferreira
AU  - Dagoberto Callegaro
AU  - Maria Fernanda Mendes
AU  - Doralina Brum
AU  - Felipe von Glehn
ED  - ,
TI  - Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders
AID  - 10.1212/NXI.0000000000001060
DP  - 2021 Nov 01
TA  - Neurology - Neuroimmunology Neuroinflammation
PG  - e1060
VI  - 8
IP  - 6
4099  - http://nn.neurology.org/content/8/6/e1060.short
4100  - http://nn.neurology.org/content/8/6/e1060.full
SO  - Neurol Neuroimmunol Neuroinflamm2021 Nov 01; 8
AB  - Background and Objectives To describe the clinical features and disease outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorder (NMOSD).Methods The Neuroimmunology Brazilian Study Group has set up the report of severe acute respiratory syndrome (SARS-CoV2) cases in patients with NMOSD (pwNMOSD) using a designed web-based case report form. All neuroimmunology outpatient centers and individual neurologists were invited to register their patients across the country. Data collected between March 19 and July 25, 2020, were uploaded at the REDONE.br platform. Inclusion criteria were as follows: (1) NMOSD diagnosis according to the 2015 International Panel Criteria and (2) confirmed SARS-CoV2 infection (reverse transcription-polymerase chain reaction or serology) or clinical suspicion of COVID-19, diagnosed according to Center for Disease Control / Council of State and Territorial Epidemiologists (CDC/CSTE) case definition. Demographic and NMOSD-related clinical data, comorbidities, disease-modifying therapy (DMT), COVID-19 clinical features, and severity were described.Results Among the 2,061 pwNMOSD followed up by Brazilian neurologists involved on the registry of COVID-19 in pwNMOSD at the REDONE.br platform, 34 patients (29 women) aged 37 years (range 8–77), with disease onset at 31 years (range 4–69) and disease duration of 6 years (range 0.2–20.5), developed COVID-19 (18 confirmed and 16 probable cases). Most patients exhibited mild disease, being treated at home (77%); 4 patients required admission at intensive care units (severe cases); and 1 patient died. Five of 34 (15%) presented neurologic manifestations (relapse or pseudoexacerbation) during or after SARS-CoV2 infection.Discussion Most NMOSD patients with COVID-19 presented mild disease forms. However, pwNMOSD had much higher odds of hospitalization and intensive care unit admission comparing with the general Brazilian population. The frequency of death was not clearly different. NMOSD disability, DMT type, and comorbidities were not associated with COVID-19 outcome. SARS-CoV2 infection was demonstrated as a risk factor for NMOSD relapses. Collaborative studies using shared NMOSD data are needed to suitably define factors related to COVID-19 severity and neurologic manifestations.AQP4=aquaporin 4; CBA=cell-based assay; CI=confidence interval; COVID-19=coronavirus disease 2019; DMT=disease-modifying therapy; MS=multiple sclerosis; NMOSD=neuromyelitis optica spectrum disorders; OR=odds ratio; pwNMOSD=patients with NMOSD; RT-PCR=reverse transcription-polymerase chain reaction; SARS=severe acute respiratory syndrome